ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0487

A Needs Assessment for the Transition into a Rheumatology Program Director Role: Survey of Current and Former Rheumatology Program Directors

Rachel Wolfe1, Fotios Koumpouras2, Anisha Dua3, Philip Seo4, Simon Helfgott5 and Beth Jonas6, 1Wake Forest Baptist Health, Winston-Salem, NC, 2Yale School of Medicine, New Haven, CT, 3Northwestern University, Chicago, IL, 4Johns Hopkins University, Baltimore, MD, 5Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 6University of North Carolina at Chapel Hill, Chapel Hill, NC

Meeting: ACR Convergence 2021

Keywords: education, medical, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Abstracts: Professional Education (0484–0487)

Session Type: Abstract Session

Session Time: 2:45PM-3:00PM

Background/Purpose: Clinical educators taking on the new role as program director (PD) must have the time and resources to learn about all the processes (e.g., accreditation, assessment) that are essential to the effective management of a fellowship training program. Lack of preparation can lead to inadequate performance and dissatisfaction with the role. We conducted a needs assessment of current and former rheumatology PDs to determine the type of support needed to become an effective rheumatology PD. The survey asked variables that might affect their transition to a leadership role (such as previous experience, fiscal and mentor support), the enthusiasm for rheumatology-specific PD mentorship, overall satisfaction with the transition, and specific resources that would have eased the transition.

Methods: An electronic survey was emailed to 186 current and former rheumatology program directors currently on the American College of Rheumatology’s Committee on Training and Workforce listserv. Survey question types included single response, multi-select and free response.

Results: Ninety (48.4%) current or former rheumatology PDs responded to the survey. Of the 90 responses, 86 (46.2%) were completed beyond the demographics questions. Respondents to the survey were evenly split between newer and more experienced PDs; 50% of respondents had been a rheumatology PD for 5 years or less in the rheumatology PD role whereas 50% of respondents had been in this role for more than 5 years. Full-time equivalent (FTE) support for PDs varied considerably, with the majority of PDs (64%) receiving less than 20% FTE for their role as program director. Eight (9 %) respondents did not receive any support for their role as PD. Of those who completed a question on their satisfaction with the transition process, only 12 (15.7%) respondents were very satisfied with their transition to becoming a PD whereas 49% (38 out of 78) where neutral, dissatisfied or very dissatisfied with the transition (Fig. 1). There was overwhelming support (88%) for a transition mentorship program for new PDs. Program directors were most interested in a curriculum that included a practical discussion of how to run a program (86.9%), developing core curriculum (46.5%) and assessment of fellows (46.5%).

Conclusion: Based on our survey of PDs, we identified several areas suitable for innovation. A mentor program for new PDs was desired by most, indicating the need for additional support and training during the PD transition period. Furthermore, FTE support was found to be less than that outlined in the Accreditation Council for Graduate Medical Education (ACGME) common program requirements (at least 20%) for the majority of the rheumatology PDs. These results should inform key stakeholders on the need for more support for PDs to include mentorship, educational content and fiscal support.


Disclosures: R. Wolfe, None; F. Koumpouras, GSK, 1, 2, 5, BMS, 5, Astra Zeneca, 1, Aurinia, 5, 6, UCB, 5, ABBvie, 5, Janssen, 5; A. Dua, Abbvie, 1, 2, 6, Novartis, 2, Chemocentryx, 2; P. Seo, Amgen, 1, Janssen, 1; S. Helfgott, None; B. Jonas, None.

To cite this abstract in AMA style:

Wolfe R, Koumpouras F, Dua A, Seo P, Helfgott S, Jonas B. A Needs Assessment for the Transition into a Rheumatology Program Director Role: Survey of Current and Former Rheumatology Program Directors [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/a-needs-assessment-for-the-transition-into-a-rheumatology-program-director-role-survey-of-current-and-former-rheumatology-program-directors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-needs-assessment-for-the-transition-into-a-rheumatology-program-director-role-survey-of-current-and-former-rheumatology-program-directors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology